MBX Biosciences, Inc. (MBX) has received a new Buy rating, initiated by JMP Securities analyst, Jonathan Wolleben.
Jonathan Wolleben has given his Buy rating due to a combination of factors related to MBX Biosciences’ innovative approach and market potential. The company is leveraging its proprietary Precision Endocrine Peptide (PEP) platform to develop peptide therapeutics with high potency and selectivity, which are designed for less frequent dosing and improved tolerability. This platform is being applied to areas with significant unmet medical needs, such as hypoparathyroidism (HP), where current treatments are inadequate for many patients.
MBX’s lead candidate, canvuparatide, is a promising weekly subcutaneous PTH prodrug for HP, expected to be preferred over existing daily treatments. The upcoming Phase 2 data in the third quarter of 2025 is a critical catalyst, with the potential to demonstrate a competitive response rate. Additionally, MBX is advancing other candidates, such as MBX 1416 for post-bariatric hypoglycemia and MBX 4291 for obesity, which could further enhance the company’s value. These strategic developments and the substantial market opportunities they target underpin Wolleben’s positive outlook on MBX Biosciences.
According to TipRanks, Wolleben is a 2-star analyst with an average return of -0.4% and a 36.66% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, KalVista Pharmaceuticals, and BioCryst.